New England Biolabs® Introduces New Ribosomal RNA Depletion Technology from
First Kit Improves RNA-Seq for FFPE and High-Quality RNA Samples
IPSWICH, Mass., Aug. 19, 2014
IPSWICH, Mass., Aug. 19, 2014 /PRNewswire/ --New England Biolabs, Inc.
(NEB^®) today announced that NEB has exclusively in-licensed rights from
Genomic Health, Inc. to its technology for the depletion of abundant RNAs,
which is instrumental to performing sensitive RNA-seq experiments at a lower
New England Biolabs logo
Ribosomal RNAs (rRNAs) are extremely abundant, constituting approximately 90%
of total RNA. For RNA sequencing experiments to be practical and
cost-effective, rRNAs must be removed from the sample in order to focus on the
RNA molecules of interest. This can be especially challenging for low input
and formalin-fixed paraffin-embedded (FFPE) RNA samples - a problem that is
addressed by Genomic Health's technology, which uses RNase H-based depletion.
The NEBNext^® rRNA Depletion Kit (Human/Mouse/Rat) is the first NEB product
based on this technology, and is highly effective for FFPE RNA samples as well
as high-quality RNA samples.
In conjunction with NEB's other innovations for next generation sequencing
(NGS), including the NEBNext Ultra™ kits and adaptors, this technology further
strengthens NEB's position as a key provider of quality products and support
to the NGS community.
"We are excited about this agreement with Genomic Health and are pleased to
offer their technology as a new NEB product. The NEBNext rRNA Depletion Kit
exhibits efficient removal of these abundant RNAs, reducing the number of
sequencing runs required and, ultimately, the overall cost of sequencing,"
said Fiona Stewart, Ph.D., NEB's Next Generation Sequencing Product Marketing
Manager. "Additionally, the kit incorporates a streamlined workflow, and is
optimized for inputs as low as 10 ng total RNA. Perhaps most exciting is the
exceptional performance of this kit with FFPE RNA samples, for which rRNA
removal has historically been very challenging. We look forward to releasing
additional products based on this technology and are delighted to make them
available to our customers to improve their RNA-seq analyses."
NEBNext products are a series of highly pure and cost-effective reagents that
facilitate DNA and RNA library preparation for next generation sequencing. The
innovative NEBNext product line includes the Ultra Library Prep kits for DNA
and RNA, which address the increasing need for fast and robust performance,
and also allow the use of low-nanogram amounts of input DNA or RNA – ensuring
optimal data quality with flexible workflows.
For more information on NEBNext reagents for library preparation, visit
^New England Biolabs, NEB, and ^NEBNEXT® is a registered trademark of New
England Biolabs, Inc.
Ultra™ is a trademark of New England Biolabs, Inc.
About New England Biolabs
Established in the mid 1970's, New England Biolabs, Inc. is the industry
leader in the discovery and production of enzymes for molecular biology
applications and now offers the largest selection of recombinant and native
enzymes for genomic research. NEB continues to expand its product offerings
into areas related to PCR, gene expression, library preparation for next
generation sequencing, cellular analysis, epigenetics and RNA analysis.
Additionally, NEB is focused on strengthening alliances that enable new
technologies to reach key market sectors. New England Biolabs is a privately
held company, headquartered in Ipswich, MA, and has extensive worldwide
distribution through a network of exclusive distributors, agents and seven
subsidiaries located in Canada, China, France, Germany, Japan, Singapore and
the UK. For more information about New England Biolabs visitwww.neb.com.
Logo - http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b
SOURCE New England Biolabs, Inc.
Contact: Deana D. Martin, Ph.D., Marketing Communications Manager, New England
Biolabs, 240 County Road, Ipswich, MA 01938, Tel: 978-380-7464, Email:
Press spacebar to pause and continue. Press esc to stop.